Ignite Creation Date:
2025-12-24 @ 7:37 PM
Ignite Modification Date:
2025-12-30 @ 12:40 AM
Study NCT ID:
NCT02638103
Status:
COMPLETED
Last Update Posted:
2021-11-09
First Post:
2015-12-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine
Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-02-26
Start Date Type:
ACTUAL
Primary Completion Date:
2018-06-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-12-08
Completion Date Type:
ACTUAL
First Submit Date:
2015-12-18
First Submit QC Date:
None
Study First Post Date:
2015-12-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-06-05
Results First Submit QC Date:
None
Results First Post Date:
2019-08-28
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-11-06
Last Update Post Date:
2021-11-09
Last Update Post Date Type:
ACTUAL